Core Viewpoint - Novo Nordisk and Shanghai Clinical Innovation Translation Research Institute signed a strategic cooperation agreement to enhance clinical research and innovation in Shanghai, aiming to accelerate the translation of innovative therapies for Chinese patients [1] Group 1: Strategic Collaboration - The collaboration will focus on three main areas: clinical innovation results translation, disease clinical cohort construction, and real-world research and big data mining [1] - The partnership aims to bridge clinical needs with industrial innovation, enhancing the quality of healthcare development in Shanghai and China [1] Group 2: Company Commitment - Novo Nordisk has been operating in China for 31 years and is recognized as a contributor to the innovation of the Chinese pharmaceutical ecosystem [1] - The company aims to expand its ecosystem to address serious chronic diseases and integrate deeply into the local pharmaceutical innovation landscape [1]